Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.

Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, Sokol ES, Frampton G, Schrock AB, Anhorn R, Reddy P.

Oncologist. 2020 Jan;25(1):e147-e159. doi: 10.1634/theoncologist.2019-0244. Epub 2019 Oct 2.

2.

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples.

Trabucco SE, Gowen K, Maund SL, Sanford E, Fabrizio DA, Hall MJ, Yakirevich E, Gregg JP, Stephens PJ, Frampton GM, Hegde PS, Miller VA, Ross JS, Hartmaier RJ, Huang SA, Sun JX.

J Mol Diagn. 2019 Nov;21(6):1053-1066. doi: 10.1016/j.jmoldx.2019.06.011. Epub 2019 Aug 22.

3.

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.

Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ.

Oncotarget. 2019 Jun 18;10(40):4018-4025. doi: 10.18632/oncotarget.26998. eCollection 2019 Jun 18.

4.

Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.

Boussemart L, Johnson A, Schrock AB, Pal SK, Frampton GM, Fabrizio D, Chalmers Z, Lotem M, Gibney G, Russell J, Chmielowski B, Ross JS, Stephens PJ, Miller VA, Ali SM.

J Am Acad Dermatol. 2019 Jun;80(6):1780-1782. doi: 10.1016/j.jaad.2018.12.020. Epub 2018 Dec 18. No abstract available.

5.

Approach to evaluating tumor mutational burden in routine clinical practice.

Truesdell J, Miller VA, Fabrizio D.

Transl Lung Cancer Res. 2018 Dec;7(6):678-681. doi: 10.21037/tlcr.2018.10.10. Review.

6.

Genome analysis and description of Xanthomonas massiliensis sp. nov., a new species isolated from human faeces.

Ndongo S, Beye M, Dubourg G, Nguyen TT, Couderc C, Fabrizio DP, Fournier PE, Raoult D, Angelakis E.

New Microbes New Infect. 2018 Jun 21;26:63-72. doi: 10.1016/j.nmni.2018.06.005. eCollection 2018 Nov.

7.

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

Fabrizio DA, George TJ Jr, Dunne RF, Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB, Hezel AF, Ross JS, Stephens PJ, Ali SM, Miller VA, Fakih M, Klempner SJ.

J Gastrointest Oncol. 2018 Aug;9(4):610-617. doi: 10.21037/jgo.2018.05.06.

8.

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.

Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F.

Oncologist. 2019 Feb;24(2):219-228. doi: 10.1634/theoncologist.2018-0058. Epub 2018 Aug 14.

9.

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.

Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, Lieber DS, Lipson D, Silterra J, Amler L, Riehl T, Cummings CA, Hegde PS, Sandler A, Ballinger M, Fabrizio D, Mok T, Shames DS.

Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6.

PMID:
30082870
10.

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.

Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R.

JAMA Oncol. 2018 Sep 1;4(9):1237-1244. doi: 10.1001/jamaoncol.2018.1701.

11.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

12.

A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin.

Wensel D, Sun Y, Davis J, Li Z, Zhang S, McDonagh T, Fabrizio D, Cockett M, Krystal M.

J Virol. 2018 Jun 29;92(14). pii: e00421-18. doi: 10.1128/JVI.00421-18. Print 2018 Jul 15.

13.

Dens invaginatus with necrotic pulp in a right maxillary lateral incisor with preserved vitality.

Alessandro L, Fabrizio DF, Gennaro M, Dario DS, Eugenio G, Letizia P, Luigi F, Felice F.

J Conserv Dent. 2018 Jan-Feb;21(1):109-113. doi: 10.4103/JCD.JCD_72_17. Erratum in: J Conserv Dent. 2019 May-Jun;22(3):318.

14.

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.

Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Sun J, Miller VA, Stephens PJ, Gay LM.

Cancer. 2018 Apr 1;124(7):1358-1373. doi: 10.1002/cncr.31125. Epub 2018 Jan 16.

15.

BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.

Johnson DB, Childress MA, Chalmers ZR, Frampton GM, Ali SM, Rubinstein SM, Fabrizio D, Ross JS, Balasubramanian S, Miller VA, Stephens PJ, Sosman JA, Lovly CM.

Pigment Cell Melanoma Res. 2018 May;31(3):432-436. doi: 10.1111/pcmr.12674. Epub 2017 Dec 16.

16.

ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.

Ross JS, Ali SM, Fasan O, Block J, Pal S, Elvin JA, Schrock AB, Suh J, Nozad S, Kim S, Jeong Lee H, Sheehan CE, Jones DM, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Miller VA, Stephens PJ, Gay LM.

Oncologist. 2017 Dec;22(12):1444-1450. doi: 10.1634/theoncologist.2016-0488. Epub 2017 Oct 27.

17.

General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.

Lee H, El Jabbour T, Ainechi S, Gay LM, Elvin JA, Vergilio JA, Suh J, Ramkissoon SH, Ali SM, Schrock A, Fabrizio D, Frampton G, Nazeer T, Miller VA, Stephens PJ, Ross JS.

Hum Pathol. 2017 Dec;70:84-91. doi: 10.1016/j.humpath.2017.10.007. Epub 2017 Oct 24.

PMID:
29079173
18.

Comprehensive Analysis of Hypermutation in Human Cancer.

Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A.

Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub 2017 Oct 19.

19.

Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.

Ross JS, Gay LM, Wang K, Vergilio JA, Suh J, Ramkissoon S, Somerset H, Johnson JM, Russell J, Ali S, Schrock AB, Fabrizio D, Frampton G, Miller V, Stephens PJ, Elvin JA, Bowles DW.

Ann Oncol. 2017 Oct 1;28(10):2539-2546. doi: 10.1093/annonc/mdx399.

20.

Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.

Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, Daniel S, Covert M, Frampton GM, Hsu S, Lesser GJ, Stogner-Underwood K, Mott RT, Rush SZ, Stanke JJ, Dahiya S, Sun J, Reddy P, Chalmers ZR, Erlich R, Chudnovsky Y, Fabrizio D, Schrock AB, Ali S, Miller V, Stephens PJ, Ross J, Crawford JR, Ramkissoon SH.

Oncologist. 2017 Dec;22(12):1478-1490. doi: 10.1634/theoncologist.2017-0242. Epub 2017 Sep 14.

21.

Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.

Wensel D, Sun Y, Li Z, Zhang S, Picarillo C, McDonagh T, Fabrizio D, Cockett M, Krystal M, Davis J.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00508-17. doi: 10.1128/AAC.00508-17. Print 2017 Aug.

22.

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.

Dagogo-Jack I, Fabrizio D, Lennerz J, Schrock AB, Young L, Mino-Kenudson M, Digumarthy SR, Heist RS, Ali SM, Miller VA, Shaw AT.

J Thorac Oncol. 2017 Oct;12(10):e155-e157. doi: 10.1016/j.jtho.2017.04.023. Epub 2017 May 9. No abstract available.

23.

First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.

Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS.

JCI Insight. 2017 Apr 20;2(8). pii: 90380. doi: 10.1172/jci.insight.90380. eCollection 2017 Apr 20.

24.

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, Garraway L, Miller VA, Stephens PJ, Frampton GM.

Genome Med. 2017 Apr 19;9(1):34. doi: 10.1186/s13073-017-0424-2.

25.

Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.

Hartmaier RJ, Charo J, Fabrizio D, Goldberg ME, Albacker LA, Pao W, Chmielecki J.

Genome Med. 2017 Feb 24;9(1):16. doi: 10.1186/s13073-017-0408-2.

26.

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.

Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM.

Cancer Immunol Res. 2016 Nov;4(11):959-967. Epub 2016 Sep 26.

27.

A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.

Emanuel SL, Engle LJ, Chao G, Zhu RR, Cao C, Lin Z, Yamniuk AP, Hosbach J, Brown J, Fitzpatrick E, Gokemeijer J, Morin P, Morse BA, Carvajal IM, Fabrizio D, Wright MC, Das Gupta R, Gosselin M, Cataldo D, Ryseck RP, Doyle ML, Wong TW, Camphausen RT, Cload ST, Marsh HN, Gottardis MM, Furfine ES.

MAbs. 2011 Jan-Feb;3(1):38-48. Epub 2011 Jan 1.

28.

FEF75 in asthma management.

Luigi DB, Emanuel DT, Federica DB, Fabrizio DT.

Eur Ann Allergy Clin Immunol. 2007 Dec;39(10):333-6.

PMID:
18386434
29.

Growth factors in plastic surgery.

Chajchir A, Fabrizio D, Chajchir G, Celi E.

Aesthetic Plast Surg. 2005 Jul-Aug;29(4):295-9.

PMID:
16075353
30.

DRAGON, a bone morphogenetic protein co-receptor.

Samad TA, Rebbapragada A, Bell E, Zhang Y, Sidis Y, Jeong SJ, Campagna JA, Perusini S, Fabrizio DA, Schneyer AL, Lin HY, Brivanlou AH, Attisano L, Woolf CJ.

J Biol Chem. 2005 Apr 8;280(14):14122-9. Epub 2005 Jan 25.

31.

Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system.

del Re E, Sidis Y, Fabrizio DA, Lin HY, Schneyer A.

J Biol Chem. 2004 Dec 17;279(51):53126-35. Epub 2004 Oct 8.

32.

DRAGON: a member of the repulsive guidance molecule-related family of neuronal- and muscle-expressed membrane proteins is regulated by DRG11 and has neuronal adhesive properties.

Samad TA, Srinivasan A, Karchewski LA, Jeong SJ, Campagna JA, Ji RR, Fabrizio DA, Zhang Y, Lin HY, Bell E, Woolf CJ.

J Neurosci. 2004 Feb 25;24(8):2027-36.

33.

The influence of noncognitive factors on the Mini-Mental State Examination in older Mexican-Americans: findings from the Hispanic EPESE. Established Population for the Epidemiologic Study of the Elderly.

Black SA, Espino DV, Mahurin R, Lichtenstein MJ, Hazuda HP, Fabrizio D, Ray LA, Markides KS.

J Clin Epidemiol. 1999 Nov;52(11):1095-102.

PMID:
10527004
34.

Correlates of prescription and over-the-counter medication usage among older Mexican Americans: the Hispanic EPESE study. Established Population for the Epidemiologic Study of the Elderly.

Espino DV, Lichtenstein MJ, Hazuda HP, Fabrizio D, Wood RC, Goodwin J, Stroup-Benham CA, Markides KS.

J Am Geriatr Soc. 1998 Oct;46(10):1228-34.

PMID:
9777904
35.

Biologic characteristics of transformed rhesus foreskin cells infected with Mason-Pfizer monkey virus.

Fine DL, Peinta RJ, Malan LB, Kubicek MT, Bennett DG, Landon JC, Valerio MG, West DM, Fabrizio DA, Chopra HC.

J Natl Cancer Inst. 1974 Apr;52(4):1135-42. No abstract available.

PMID:
4207874
36.

A human leukocyte culture with an unusual cytoplasmic envelopment of herpes-type particles.

Chandra S, Korol W, Ames RP, Fabrizio DP, Jensen EM.

Cancer Res. 1971 Apr;31(4):441-7. No abstract available.

37.

Herpes-type virus in cultured leukocytes from chimpanzees.

Landon JC, Ellis LB, Zeve VH, Fabrizio DP.

J Natl Cancer Inst. 1968 Jan;40(1):181-92. No abstract available.

PMID:
5635017
38.

Tumors in rhesus monkeys inoculated at birth with homologous cells converted in vitro by Rous sarcoma virus, Schmidt-Ruppin strain.

Rabotti GF, Landon JC, Pry TW, Beadle L, Doll J, Fabrizio DP, Dalton AJ.

J Natl Cancer Inst. 1967 Jun;38(6):821-37. No abstract available.

PMID:
4290691
39.

FURTHER STUDIES ON THE ELECTRON MICROSCOPY OF THE H-1 VIRUS.

TOOLAN HW, SAUNDERS EL, GREENE EL, FABRIZIO DP.

Virology. 1964 Feb;22:286-8. No abstract available.

PMID:
14165336
40.

Mongolism with mosaic chromosome pattern.

NICHOLS WW, CORIELL LL, FABRIZIO DP, BISHOP HC, BOGGS TR Jr.

J Pediatr. 1962 Jan;60:69-76. No abstract available.

PMID:
14479460
41.

Comparison of PPLO strains from tissue culture by complement fixation.

CORIELL LL, FABRIZIO DP, WILSON SR.

Ann N Y Acad Sci. 1960 Jan 15;79:574-80. No abstract available.

PMID:
13811975

Supplemental Content

Loading ...
Support Center